You don’t have permission to access “http://www.alvarezandmarsal.com/press-release/turnaround-industry-survey-signs-of-recovery-overshadowed-by-persistent-business-struggles” on this server.
Reference…
Category: 6. Business
-
Access Denied
Access Denied
-
Week Ahead for FX, Bonds: U.S. Inflation, PMI -2-
For September, retail sales, a key gauge of consumption, likely grew 3.0% on year, down from August’s 3.4% increase, the poll shows. Industrial production is estimated to have grown 5.3%, marginally above August’s 5.2%. Fixed-asset investment…
Continue Reading
-
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity USA – English APAC – English APAC – Traditional Chinese
– The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment…
Continue Reading
-
ESMO 2025: GFH375 Shows Potential Against KRAS G12D Pancreatic Tumours
Oncogenic KRAS mutations, particularly the G12D variant, are the most common drivers of pancreatic ductal adenocarcinoma (PDAC), accounting for roughly 40% of cases and predicting a poorer prognosis. This mutation is a crucial target for new…
Continue Reading
-
ESMO 2025: Multi Cycle Dosimetry of the Albumin Binding PSMA Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Castration Resistant Prostate Cancer: Phase II Trial Results – UroToday
- ESMO 2025: Multi Cycle Dosimetry of the Albumin Binding PSMA Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Castration Resistant Prostate Cancer: Phase II Trial Results UroToday
- ASTRO: New therapy delays progression of recurrent prostate cancer
Continue Reading
-
New Zealand's annual inflation hits 3%, top of central bank's target band – Reuters
- New Zealand’s annual inflation hits 3%, top of central bank’s target band Reuters
- Inflation hits 3% as consumers suffer largest power price spike since 1989 NZ Herald
- Consumer Price Index: Inflation increases to 3 percent, highest level in year
Continue Reading
-
ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus Placebo + Abiraterone in Patients with PTEN-deficient De Novo Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281 – UroToday
- ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus Placebo + Abiraterone in Patients with PTEN-deficient De Novo Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281 UroToday
- Truqap Extends Radiographic…
Continue Reading
-
Bispecific ADC Iza-Bren Leads to Improved ORR Vs Chemo in Nasopharyngeal Cancer | Targeted Oncology
Patients treated with izalontamab brengitecan (iza-bren; BL-B01D1) had superior overall response rate (ORR) compared with chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to results from the…
Continue Reading
-
Jensen Huang says Nvidia went from 95% market share in China to 0%
Nvidia CEO Jensen Huang urged nuance when it comes to regulating China’s access to U.S. technologies that are critical to developing artificial intelligence.
In an interview with Citadel Securities on Tuesday, he warned that what harms China…
Continue Reading
